Review: Methods of synthesis of erlotinib and its derivatives as tyrosine kinase inhibitor in 2020-2025

This review focuses on the most important synthetic approaches to produce erlotinib and its derivatives, shows changes in their structure that minimized toxicity, surpassed resistance mechanisms, increased selectivity and improved therapeutic efficacy, The latest applications of green and medicinal chemistry and recent developments are covered. Erlotinib, a type of targeted cancer drug has been widely studied and modified over the past five years., it has already available in US, EU, Japan and other 100 countries worldwide since approved for medical use in 2004. Erlotinib is a first-generation inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. It is cleared to treat non-small cell lung cancer, pancreatic cancer and a few other cancer. Its brand name is usually Tarceva. The presented review contains the following issue: summary of references concerning the synthesis methods, structure-activity correlation ship (SAR) or biological parameters related to erlotinib family analogues (from 2020 to 2025).